Evidence-Based Medical News

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Genetics & Precision Medicine Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Urology Ophthalmology Dermatology Emergency Medicine Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

brentuximab vedotin

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of brentuximab vedotin

38 trials tracked of brentuximab vedotin: 7 in phase 3 or 4 and 3 with published results. The most-cited published study has 728 citations.

38Trials tracked

7Phase 3 & 4

0Recruiting

3With published results

Phase distribution

Phase 4 3 Phase 3 4 Phase 2 29 Phase 1 1 Other / NA 1

Phase 3 ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Completed · 728 cited
Phase 3 A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) Completed · 587 cited
Phase 3 A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma Completed · 330 cited
Phase 4 A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma Completed
Phase 4 Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Completed
Phase 4 A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma Completed

Show 32 more trials

Phase 3 A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial) Completed
Phase 2 A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Completed
Phase 2 Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma Completed
Phase 2 Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL) Completed
Phase 2 A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma Completed
Phase 2 An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas Completed
Phase 2 Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas Completed
Phase 2 Brentuximab Vedotin for Systemic Sclerosis Completed
Phase 2 Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma Completed
Phase 2 Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma Completed
Phase 2 A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study Completed
Phase 2 Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level Completed
Phase 2 A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Completed
Phase 2 Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies Completed
Phase 2 Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia Completed
Phase 2 Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Completed
Phase 2 Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma Completed
Phase 2 A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment Completed
Phase 2 Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma Completed
Phase 2 A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma Completed
Phase 2 Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients Completed
Phase 2 Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Completed
Phase 2 A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) Completed
Phase 2 A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression Completed
Phase 2 A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL Completed
Phase 2 A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma Completed
Phase 2 Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma Completed
Phase 2 Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma Completed
Phase 2 Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma Completed
Phase 2 Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma Completed
Phase 1 A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma Completed
N/A Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma Completed

Showing the 38 most-cited and recently-updated of 38 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.